NAD questions dietary supplement’s safety; submits concerns to FTC, FDA
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday referred advertising from Metabolic Research around its Stemulite dietary supplement to the Federal Trade Commission and Food and Drug Administration for further review, following the company’s decision not to participate in an NAD review of advertising for the product.
As a part of its ongoing monitoring program and in conjunction with an initiative with the Council for Responsible Nutrition to expand the review of advertising claims for dietary supplements, NAD – the advertising industry’s self-regulatory forum – requested that the company provide supporting evidence for advertising claims including,“People who take Stemulite experience deep REM sleep, increased muscle gain and endurance, increased weight loss and fat loss and increased wellness and energy.”
As part of its review, NAD also expressed concerned about several testimonials on the Stemulite Web site.
The advertiser contacted NAD, and despite requesting and being given an extension of time within which to file its response, failed to do so. The advertiser represented to NAD that it would be conducting a study in the future and would participate after the completion of the study.
NAD noted that it is a well-settled principle of advertising law that an advertiser must possess adequate substantiation before it publishes advertising claims. NAD’s procedures provide that if an advertiser does not participate in the process, NAD may refer the advertising at issue to the appropriate government agency for further review.
NAD was “disappointed that the advertiser did not participate in the NAD inquiry, particularly in light of the health and weight-loss claims being made.” Based on the advertiser’s failure to participate, NAD will refer this matter to the FTC and FDA for possible law enforcement action.
Scientists uncover immune system’s role in bone loss
LOS ANGELES A new UCLA study sheds light on the link between high cholesterol and osteoporosis and identifies a new way that the body’s immune cells play a role in bone loss, the University announced Monday.
Published Aug. 20 in the journal Clinical Immunology, the research could lead to new immune-based approaches for treating osteoporosis, authors of the study noted. Affecting 10 million Americans, the disease causes fragile bones and increases the risk of fractures, resulting in lost independence and mobility.
Scientists have long recognized the relationship between high cholesterol and osteoporosis, but pinpointing the exact mechanism connecting the two has proved elusive.
“We’ve known that osteoporosis patients have higher cholesterol levels, more severe clogging of the heart arteries and increased risk of stroke. We also knew that drugs that lower cholesterol reduce bone fractures, too,” explained Rita Effros, professor of pathology at the David Geffen School of Medicine at UCLA. “What we didn’t understand was why.”
In the study, UCLA researchers focused on low-density lipoprotein (LDL) and examined how high levels of oxidized LDL affect bone and whether a type of immune cell called a T cell plays a role in the process.
Using blood samples from healthy human volunteers, the team isolated the participants’ T cells and cultured them in a dish. Half of the T cells were combined with normal LDL – the rest was combined with oxidized LDL. The scientists stimulated half of the T cells to mimic an immune response and left the other half alone.
“Both the resting and the activated T cells started churning out a chemical that stimulates cells whose sole purpose is to destroy bone,” Effros said. Called RANKL, the chemical is involved in immune response and bone physiology.
When Effros and her colleagues tested the T cells of the mice on the high-fat diet, they discovered that the cells acted differently than those of the mice on a normal diet.
The T cells switched on the gene that produces RANKL. The chemical also appeared in the animals’ bloodstream, suggesting that the cellular activity contributed to their bone loss.
“It’s normal for our T cells to produce small amounts of RANKL during an immune response,” explained Effros. “But when RANKL is manufactured for long periods or at the wrong time, it results in excessive bone damage.”
An entire endcap of nothing but hand sanitizer
When’s the last time an entire endcap has been dedicated against hand sanitizer?
That’s the power of the novel H1N1 pandemic flu that will be returning to a school/workplace near you this fall. What are the chances this endcap will be rampant with empty spaces after the first few months of the season?
Probably not pretty good, but only because CVS will likely fill that space with something else. Even with a heightened retail focus around sanitizers this year, the demand on hand sanitizers may just be that great.